The Cost-effectiveness of Routine Office-based Identification and Subsequent Medical Treatment of Primary Open-Angle Glaucoma in the United States

Ophthalmology

Volumn 116, Issue 5, 2009, Pages 823-832

  Rein, David B ^a   Wittenborn, John S ^a   Lee, Paul P ^b   Wirth, Kathleen E ^c   Sorensen, Stephen W ^d   Hoerger, Thomas J ^a   Saaddine, Jinan B ^d  

^a RTI INTERNATIONAL   (United States)

^b DUKE UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONIC ACID DERIVATIVE; PROSTAGLANDIN DERIVATIVE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPARATIVE STUDY; COMPUTER MODEL; COMPUTER SIMULATION; CONSERVATIVE TREATMENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEATH; DIAGNOSTIC TEST; DISEASE COURSE; EYE CARE; HEALTH CARE COST; INCIDENCE; INTRAOCULAR PRESSURE; MEDICAL EXAMINATION; NURSING HOME; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TRABECULOPLASTY; TRABECULOTOMY; TREATMENT OUTCOME; UNITED STATES; VISUAL FIELD;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DISABILITY EVALUATION; DISEASE PROGRESSION; FILTERING SURGERY; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, BIOLOGICAL; NURSING HOMES; PHYSICIANS' OFFICES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VISION DISORDERS; VISUAL FIELDS;

EID: 65349119179     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.12.056     Document Type: Article

References (51)

1. Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 122 (2004) 532-538
2. Leske M.C., Heijl A., Hussein M., et al., Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 121 (2003) 48-56
3. Rein D.B., Zhang P., Wirth K.E., et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 124 (2006) 1754-1760
4. U.S. Preventive Services Task Force. Screening for glaucoma: recommendation statement. Ann Fam Med 3 (2005) 171-172
5. Kymes S.M., Kass M.A., Anderson D.R., et al., Ocular Hypertension Treatment Study Group (OHTS). Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 141 (2006) 997-1008
6. U.S. Census Bureau. Population estimates. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2003 (NC-EST2003-01). http://www.census.gov/popest/national/asrh/NC-EST2003/NC-EST2003-01.pdf Accessed November 25, 2008
7. Colton T., and Ederer F. The distribution of intraocular pressures in the general population. Surv Ophthalmol 25 (1980) 123-129
8. National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2002. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm Accessed September 11, 2008
9. Wittenborn J.S., and Rein D.B. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. http://www.rti.org/pubs/updated_glaucoma_technical_report_20081214_2_pdf Accessed December 15, 2008
10. Rein D.B., Saaddine J.B., Wittenborn J.S., et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology 114 (2007) 1319-1326
11. Leske M.C., Connell A.M., Wu S., et al., Barbados Eye Studies Group. Incidence of open-angle glaucoma: the Barbados Eye Study. Arch Ophthalmol 119 (2001) 89-95
12. McKean-Cowdin R., Varma R., Wu J., et al., Los Angeles Latino Eye Study Group. Severity of visual field loss and health-related quality of life. Am J Ophthalmol 143 (2007) 1013-1023
13. Chen P.P. Correlation of visual field progression between eyes in patients with open-angle glaucoma. Ophthalmology 109 (2002) 2093-2099
14. Heijl A., Leske M.C., Bengtsson B., et al., Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120 (2002) 1268-1279
15. Rein D.B., Wirth K.E., Johnson C.A., and Lee P.P. Estimating quality-adjusted life year losses associated with visual field deficits using methodological approaches. Ophthalmic Epidemiol 14 (2007) 258-264
16. National Center for Health Statistics. National Ambulatory Medical Care Survey. Public-use data files (micro-data) (1973-2006). NAMCS 1993-2006 (files NAMCS02.exe and readme02.txt). http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm Accessed September 11, 2008
17. Harper R., and Reeves B. The sensitivity and specificity of direct ophthalmoscopic optic disc assessment in screening for glaucoma: a multivariate analysis. Graefes Arch Clin Exp Ophthalmol 238 (2000) 949-955
18. Sommer A., Enger C., and Witt K. Screening for glaucomatous visual field loss with automated threshold perimetry. Am J Ophthalmol 103 (1987) 681-684
19. Sponsel W.E., Ritch R., Stamper R., et al., Prevent Blindness America Glaucoma Advisory Committee. Prevent Blindness America visual field screening study. Am J Ophthalmol 120 (1995) 699-708
20. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern. Primary open-angle glaucoma (1996), American Academy of Ophthalmology, San Francisco, CA. http://one.aao.org/CE/PracticeGuidelines/PPP.aspx Accessed September 11, 2008
21. Zhou Z., Althin R., Sforzolini B.S., and Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol 88 (2004) 1391-1394
22. Reardon G., Schwartz G.F., and Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 137 suppl (2004) S3-S12
23. Stein J.D., Ayyagari P., Sloan F.A., and Lee P.P. Rates of glaucoma medication utilization among persons with primary open-angle glaucoma, 1992 to 2002. Ophthalmology 115 (2008) 1315-1319
24. Nordstrom B.L., Friedman D.S., Mozaffari E., et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 140 (2005) 598-606
25. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS). 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology 111 (2004) 651-664
26. Lichter P.R., Musch D.C., Gillespie B.W., et al., CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 (2001) 1943-1953
27. Danias J., and Podos S.M. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures: the effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. [letter]. Am J Ophthalmol 127 (1999) 623-624
28. American Medical Association. Current Procedural Terminology: CPT 2006. Standard Edition. vol. 17 (2005), Thomson Delmar Learning, Florence, KY 1-582
29. Red Book: Pharmacy's Fundamental Reference. 2004 ed. (2004), Thomson Healthcare, Montvale, NJ 1-800
30. Ingenix. The Essential RBRVS, 2003 (2003), St. Anthony's Publications, Salt Lake City, UT 1-836
31. Wang J.J., Mitchell P., Cumming R.G., and Smith W. Visual impairment and nursing home placement in older Australians: the Blue Mountains Eye Study. Ophthalmic Epidemiol 10 (2003) 3-13
32. Georgia State University, and Georgia Health Policy Center. Comparative assessment of cost and care outcomes among Georgia's community-based and facility-based long-term care programs final report (2004) 1-101. http://aysps.gsu.edu/ghpc/long_term_care/reports/ltc_partnership_final_report022005.pdf Accessed September 11, 2008
33. Weinstein M.C., O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6 (2003) 9-17
34. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
35. van Hout B.A., Al M.J., Gordon G.S., and Rutten F.F. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3 (1994) 309-319
36. AREDS Research Group. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS report no. 13. Arch Ophthalmol 122 (2004) 716-726
37. Freeman E.E., Egleston B.L., West S.K., et al. Visual acuity change and mortality in older adults. Invest Ophthalmol Vis Sci 46 (2005) 4040-4045
38. Knudtson M.D., Klein B.E., and Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol 124 (2006) 243-249
39. Thiagarajan M., Evans J.R., Smeeth L., et al. Cause-specific visual impairment and mortality: results from a population-based study of older people in the United Kingdom. Arch Ophthalmol 123 (2005) 1397-1403
40. Grodum K., Heijl A., and Bengtsson B. Glaucoma and mortality. Graefes Arch Clin Exp Ophthalmol 242 (2004) 397-401
41. Hutubessy R., Chisholm D., Tan-Torres Edejer T., et al. Generalized cost-effectiveness analysis for national-level priority setting in the health sector. Cost Eff Resour Alloc 1 (2003) 1-8
42. Lee P.P., Feldman Z.W., Ostermann J., et al. Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. Ophthalmology 110 (2003) 1952-1959
43. Friedman D.S., Nordstrom B., Mozaffari E., and Quigley H.A. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology 112 (2005) 1500-1504
44. Coleman A.L., Yu F., and Rowe S. Visual field testing in glaucoma Medicare beneficiaries before surgery. Ophthalmology 112 (2005) 401-406
45. Hattenhauer M.G., Johnson D.H., Ing H.H., et al. The probability of blindness from open-angle glaucoma. Ophthalmology 105 (1998) 2099-2104
46. Quigley H.A., and Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 38 (1997) 83-91
47. Committee on Disability Determination for Individuals with Visual Impairments. In: Lennie P., and Van Hemel S.B. (Eds). National Research Council. Visual Impairments: Determining Eligibility for Social Security Benefits (2002), National Academy Press, Washington, DC 1-354. http://books.nap.edu/catalog.php?record_id=10320#toc Accessed November 25, 2008
48. Lee B.S., Kymes S.M., Nease Jr. R.F., et al. The impact of anchor point on utilities for 5 common ophthalmic diseases. Ophthalmology 115 (2008) 898-903
49. Frick K.D., Gower E.W., Kempen J.H., and Wolff J.L. Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 125 (2007) 544-550
50. Taylor H.R., Pezzullo M.L., and Keeffe J.E. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 90 (2006) 272-275
51. Henson D.B., and Shambhu S. Relative risk of progressive glaucomatous visual filed loss in patients enrolled and not enrolled in a prospective longitudinal study. Arch Ophthalmology 124 (2006) 1405-1408